Opinion
Video
Considerations for Switching Systemic Agents in Atopic Dermatitis
Panelists discuss the prevalence of treatment-refractory moderate to severe atopic dermatitis, noting factors such as intolerance or inability to use high-potency topical agents as common reasons for treatment failure, and emphasize the importance of considering alternative agents or switching treatments when necessary, particularly in pediatric patients, with biologics and Janus kinase (JAK) inhibitors being key options as evidenced by studies such as Blauvelt 2023, Keow & Abu-Hilal 2024 , and JADE EXTEND.
Video content above is prompted by the following:
- How prevalent is treatment-refractory moderate to severe atopic dermatitis?
- What are other reasons for treatment failure (eg, intolerance, inability to use high-potency topical agents)?
- When do you consider adding or switching agents?
- What other treatment options exist for pediatric atopic dermatitis?
- How do you determine which treatment to switch to?
- Biologic to JAK inhibitor: Blauvelt 2023, Keow & Abu-Hilal 2024, JADE EXTEND, Shi 2022
Related Videos
Related Content
